Staff Directory Contact Us

The Nathan S. Kline Institute for Psychiatric Research

Content

Displaying 1 - 100 of 493

Center for Dementia Research Presents

a virtual seminar by

 

Dr. Catia Teixeira

Emotional Brain Institute, NKI

 

“Early-life environmental factors regulating the serotonergic system -

Impact on the dopaminergic system and motivation”

 

Hosted By: Dr. Efrat Levy

 

Time: 10am -11am

Thursday October 15th 2020

 

Join Zoom Meeting

https://nyulangone.zoom.us/j/97408142946?pwd=aVJiSjRndFB3azlsdExabmdBNFZadz09

Time: Oct 15, 2020 10:00 AM Eastern Time (US and Canada)

 

Meeting ID: 974 0814 2946

Password: 533302

One tap mobile

+16465189805,,97408142946# US (New York)

+12133388477,,97408142946# US (Los Angeles)

 

Find your local number: https://nyulangone.zoom.us/u/abqdT1uDsu

 

Join by SIP

97408142946@zoomcrc.com

 

The Center for Biomedical Imaging and Neuromodulation presents

Dr. Jonathan Power, MD

Sackler Institute for Developmental Neurobiology, Department of Psychiatry, Weill Cornell Medical College

Elements of fMRI scans in healthy young adults at rest

Monday, December 16, 2019

11:00 A.M. - 12:00 P.M.

Center for Biomedical Imaging and Neuromodulation Seminar Series

Xiaofu He, Ph.D.

Assistant Professor of Clinical Neurobiology, Division of Child and Adolescent Psychiatry, Department of Psychiatry

Columbia University Medical Center

Faculty Member, Data Science Institute, Columbia University and Research Scientist, New York State Psychiatric Institute

Real-time fMRI Neurofeedback for Mental Disorders Research

Monday, November 25, 2019, 11:00 a.m.

Center for Dementia Research Neuroscience Seminar Series

Daniel A. Nicholson, Ph.D.

Associate Professor, Department of Neurological Sciences

Rush University Medical Center, Chicago

Synaptic and Dendritic Mechanisms of Brain Dysfunction in Cognitive Aging and Alzheimer's Disease

Thursday, November 21, 2019, 10:00 am

Nathan Kline Institute Science Day

Tuesday, September 24th, 2019

11:00 am – 3:00 pm

NKI Auditorium

 

11:00 - 11:10 am

Welcome and Introduction

Melissa Alldred, PhD

Research Scientist, Center for Dementia Research, Nathan Kline Institute

 

11:10 - 11:25 am

Resting-State Functional Connectivity Underlying Interoception in Obsessive-Compulsive Disorder

Goi Khia Eng, PhD

Postdoctoral Fellow, Clinical Research, Nathan Kline Institute

 

11:25 - 11:40 am

Perinatal interference with the serotonergic system affects VTA function in the adult via glutamate co-transmission

Catia M. Teixeira, PhD

Research Scientist, Emotional Brain Institute, Nathan Kline Institute

 

11:40 - 11:55 am

Trk inhibition in a new experimental model of seizures and spreading depolarization/spreading depression

Yi-Ling Lu, PhD

Postdoctoral Fellow, Center for Dementia Research, Nathan Kline Institute

 

11:55 - 12:10 pm

CB1R Mediated CDK5 and RAC1 Signaling Control Neurobehavioral Abnormalities in Postnatal Ethanol Exposed Mice

Basavaraj S. Balapal, PhD

Research Scientist, Analytical Psychopharmacology, Nathan Kline Institute

 

12:10 - 12:25 pm

Effects of neonatal ethanol on GABA neuron development through adolescence

John F. Smiley, PhD

Research Scientist, Neurochemistry, Nathan Kline Institute

 

12:25 - 12:30 pm

Closing Remarks

Alexandre Franco, PhD

Research Scientist, Center for Biomedical Imaging and Neuromodulation, Nathan Kline Institute

 

12:30 - 1:00 pm

Break with Refreshments/ Poster placement

 

1:00 - 3:00 pm

Poster Session

Conference Rooms A-C

 

 

 

FREE MEMORY SCREENING AND EDUCATION EVENT

At the Nathan S. Kline Institute for Psychiatric Research

When:

By Appointment

10AM – 4PM

Friday, May 17, 2019

 

Where:

Geriatric Psychiatry Division

140 Old Orangeburg Rd, Bldg 35

Orangeburg, NY 10962

 

We will be offering a free 10-to-15-minute memory test to the public. Call to make your appointment. Additionally, resources and educational materials will be provided to create awareness about the current treatment options for Alzheimer’s, the clinical research being conducted to date (especially those being conducted at our site), and the processes of healthy brain aging. Our experienced staff will also be present to field questions and have personal discussions with individuals who wish to learn more.

 

For more information, or to schedule your appointment,

please contact Katie Brundage at (845) 398-6533.

 

The Clinical Research Department at the Nathan Kline Institute presents

 

BRAIN HEALTH: DEPRESSION AND OCD

 

Leading experts Dan Iosifescu, MD and Emily Stern, PhD will speak about Depression and Obsessive Compulsive Disorder

 

OPEN TO THE PUBLIC

Come hear about the latest research, enjoy light refreshments, and have your questions about depression & OCD answered.

 

Monday November 5, 2018

6 pm – 7:30 pm

Nathan Kline Institute for Psychiatric Research

35 Third Avenue, Orangeburg, NY

 

RSVP Recommended: Call 845-398-7752 or email depression@nki.rfmh.org

 

 

Please join NAMI Rockland and The Nathan Kline Institute for a presentation by Dr. Lloyd Sederer, Chief Medical Officer of the NYS Office of Mental Health, on his new book: The Addiction Solution: Treating our Dependence on Opioids and Other Drugs. In this book, Dr. Sederer combines his scientific and clinical knowledge to establish a clear path to recovery and health through our current drug crisis.

Refreshments will be available, and the presentation will be followed by a Q&A and a book signing.

To RSVP, call NAMI Rockland at (845) 359-8787.

Free Family event with fun activities for all ages!

Come to BRAIN DAY at the Nathan Kline Institute in Orangeburg, NY. Learn all about the brain and touch a real human brain! Play brain games! Go on a tour of the state-of-the-art Brain Imaging Suite and talk to researchers about careers in brain science. Hear talks by experts in brain science and mental health. Learn how you can contribute to brain research. Resources for parents and teachers and complimentary refreshments provided. All ages welcome.

The talks take place in one room and the activities are in another. The activities area is open and accessible all day. We have tours of our brain imaging suite where people can see how our research team safely takes pictures of the brain.  Brain imaging researchers will be on hand to discuss the process from the physics of the machine to the details of what it is like to lie down and take a picture of one’s own brain.

Here are some of the activities:

  • View and touch human brain specimens (with gloves!) and learn about brain anatomy.
  • For the younger set, make neurons out of pipe cleaners, solve brain puzzles on paper and color illustrations of brains and neurons.
  • See and hear visual and auditory illusions that demonstrate about how the brain is organized.
  • Participate in a distracted driving simulation that demonstrates the dangers of trying to multitask on the road and teaches why this is a cognitive challenge.
  • Experience the power of automatic behaviors (like reading) and learn how scientists measure the ability to override those automatic behaviors with a simple color naming test.
  • Talk to research scientists about careers in brain science and how you can contribute to research.

Wednesday August 23, 2017 9:30am – 1:00pm

Schedule:

9:30                        Doors open

10:00 – 10:15        Welcome to NKI by Kristin Dietz Trautman, LCSW

10:15 – 11:00        How We Study the Brain and What We Know by Michael Milham, MD PhD

11:00 – 12:30        Tours of Research Areas and Brain Imaging Suite

1:00                        End of event

Reservations are recommended for all events. Learn more about the NKI Rockland Sample project at rocklandsample.org.

Call (845) 398-2666 or email RocklandSample@nki.RFMH.org.

Nathan Kline Institute 35 Third Ave (off Old Orangeburg Rd.) Orangeburg, NY 10962

 

Clozapine for the Prevention of Violence in Schizophrenia: A Randomized Clinical Trial

Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs. antipsychotic treatment as usual (TAU) for reducing the risk of violent acts in real-world settings.

Study Length: 
24 weeks
Disorder/Condition: 
Schizophrenia
Inclusion Criteria: 
  • DSM-5 diagnosis of schizophrenia or schizoaffective disorder
  • Committed a minor or serious act of violence as measured by the MCVI in the last six months
  • 18 to 65 years old
  • Appropriate for treatment with either clozapine or TAU
Study Title (brief): 
Clozapine for the Prevention of Violence in Schizophrenia: A Randomized Clinical Trial
Study Description (brief): 

Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs. antipsychotic treatment as usual (TAU) for reducing the risk of violent acts in real-world settings.

Study Contact: 

For more information about this study, please contact Seth Eaton, research coordinator, at 646-766-5864 or Seth.Eaton@omh.ny.gov.

Exclusion Criteria: 
  • An unstable or serious medical or neurological condition
  • A history of intolerance/allergy to clozapine
  • A history of intellectual impairment
  • Pregnant or lactating women; women who are able to become pregnant but who are not willing to use effective methods of birth control.
Study Location: 
Manhattan Psychiatric Center, 102 Rivers Edge Road, New York, NY 10035 AND Manhattan Psychiatric Center Outpatient Clinic, 163 West 125th Street, New York, NY 10027

Heterogeneity in OCD and Depression

This project aims to comprehensively characterize heterogeneity in Obsessive-Compulsive Disorder (OCD) and Major Depressive Disorder (MDD) in order to identify behavioral and neural markers that can be used as targets for future treatments.

Study Length: 
3 visits: The first taking 3-4 hours, the second taking 1-2 hours, and the third taking 3-5 hours. The total number of hours will be approximately 7-11 hours.
Disorder/Condition: 
Depression
Inclusion Criteria: 

Men and women between the ages of 18-55 years old who have obsessive-compulsive disorder or major depressive disorder. Participants should be in good general health.

Study Title (brief): 
Heterogeneity in OCD and Depression
Study Description (brief): 

This project aims to comprehensively characterize heterogeneity in Obsessive-Compulsive Disorder (OCD) and Major Depressive Disorder (MDD) in order to identify behavioral and neural markers that can be used as targets for future treatments.

Study Contact: 

Nicolette Recchia at 845-398-5590 or pnclab@nki.rfmh.org.

Study Location: 
Nathan Kline Institute, Orangeburg, NY and New York University Medical Center, NY, NY

Heterogeneity in OCD and Depression

This project aims to comprehensively characterize heterogeneity in Obsessive-Compulsive Disorder (OCD) and Major Depressive Disorder (MDD) in order to identify behavioral and neural markers that can be used as targets for future treatments.

Study Length: 
3 visits: The first taking 3-4 hours, the second taking 1-2 hours, and the third taking 3-5 hours. The total number of hours will be approximately 7-11 hours.
Disorder/Condition: 
Obsessive Compulsive Disorder (OCD)
Inclusion Criteria: 

Men and women between the ages of 18-55 years old who have obsessive-compulsive disorder or major depressive disorder. Participants should be in good general health.

Study Title (brief): 
Heterogeneity in OCD and Depression
Study Description (brief): 

This project aims to comprehensively characterize heterogeneity in Obsessive-Compulsive Disorder (OCD) and Major Depressive Disorder (MDD) in order to identify behavioral and neural markers that can be used as targets for future treatments.

Study Contact: 

Nicolette Recchia at 845-398-5590 or pnclab@nki.rfmh.org.

Study Location: 
Nathan Kline Institute, Orangeburg, NY and New York University Medical Center, NY, NY

Biobehavioral Predictors of Illness Progression in Adolescent Depression

The primary objective of this joint study with Albert Einstein and Mt. Sinai Medical Centers is to understand mechanisms driving recovery, persistence, or progression of depressive symptoms in teens.

Study Length: 
2 years
Disorder/Condition: 
Depression
Inclusion Criteria: 

Males and Females, ages 13-17 with depression

Study Title (brief): 
Biobehavioral Predictors of Illness Progression in Adolescent Depression
Study Description (brief): 

The primary objective of this joint study with Albert Einstein and Mt. Sinai Medical Centers is to understand mechanisms driving recovery, persistence, or progression of depressive symptoms in teens.

Study Contact: 

Clinical Evaluation Center at 845-398-2184 or vrp@nki.rfmh.org

Study Location: 
Nathan Kline Institute, Orangeburg, NY

A Three-arm, Parallel Group, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in a 13- to 17-year-old Autism Spectrum Disorder Population

The primary objective of this study is to evaluate the effectiveness and safety of an investigational medication compared with placebo in improving irritability symptoms in individuals with ASD.

Study Length: 
Approximately 4 months
Disorder/Condition: 
Autism
Inclusion Criteria: 

Males and Females, ages 13-17 with ASD and presence of irritability and GI symptoms

Study Title (brief): 
A Three-arm, Parallel Group, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in a 13- to 17-year-old Autism Spectrum Disorder Population
Study Description (brief): 

The primary objective of this study is to evaluate the effectiveness and safety of an investigational medication compared with placebo in improving irritability symptoms in individuals with ASD.

Study Contact: 

Clinical Evaluation Center at 845-398-2184 or vrp@nki.rfmh.org

Study Location: 
Nathan Kline Institute, Orangeburg, NY

A Phase II Multicenter, Randomized, Double-Blind, 12-Week Treatment, 3-Arm, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of RO7017773 in Participants Aged 15 to 45 Years with Autism Spectrum Disorder (ASD)

The primary objective of this study is to evaluate the effectiveness and safety of RO7017773, a new medication, compared with placebo in the improvement of symptoms of ASD.

Study Length: 
Approximately 5.5 months
Disorder/Condition: 
Autism
Inclusion Criteria: 

Males and Females, ages 15-45 with ASD

Study Title (brief): 
A Phase II Multicenter, Randomized, Double-Blind, 12-Week Treatment, 3-Arm, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of RO7017773 in Participants Aged 15 to 45 Years with Autism Spectrum Disorder (ASD)
Study Description (brief): 

The primary objective of this study is to evaluate the effectiveness and safety of RO7017773, a new medication, compared with placebo in the improvement of symptoms of ASD.

Study Contact: 

Clinical Evaluation Center at 845-398-2184 or vrp@nki.rfmh.org

Study Location: 
Nathan Kline Institute, Orangeburg, NY

Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression (TRIADE)

Do you have depression? Are you interested in experimental treatments for depression and contributing to depression research? If so, you may qualify to participate in our research study at NKI, IRB Study # i20-00217, that is investigating an experimental treatment device for depression using near-infrared light therapy.

Study Length: 
6-12 weeks
Disorder/Condition: 
Depression - Major Depressive Disorder (MDD)
Inclusion Criteria: 

18-65 years old

Study Title (brief): 
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression (TRIADE)
Study Description (brief): 

Do you have depression? Are you interested in experimental treatments for depression and contributing to depression research? If so, you may qualify to participate in our research study at NKI, IRB Study # i20-00217, that is investigating an experimental treatment device for depression using near-infrared light therapy.

Study Contact: 

Zamfira Parincu at 845-398-6571 or Zamfira.Parincu@nki.rfmh.org

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 in Patients with Schizophrenia or Schizoaffective Disorder And Negative Symptoms; Protocol BP40283

RO6889450 is a novel compound and a potent partial agonist of Trace Amine-Associated Receptor 1 (TAAR1) for the treatment of negative symptoms in schizophrenia. This site is conducting Part B (add-on therapy) wherein participants will be randomized 1:1:1 to 45 mg QD of RO6889450, 150 mg QD of RO6889450, or placebo for 12 weeks. Stratification will be based on BNSS avolition/apathy subscore (sum of items “behavior” and “internal experience”; ≤6 vs. >6), age (18-35 years vs. 36-55 years), sex, and antipsychotic treatment (1:1 stratification ratio between dopamine 2 receptor [D2]/serotonin 2A [5HT2A] receptor antagonists and D2 partial agonist).

Study Length: 
Twenty weeks. Study participants will need to come at least 11 times to the study site during the study period.
Disorder/Condition: 
Schizophrenia
Inclusion Criteria: 
  • Stable outpatients with DSM-5 diagnosis of schizophrenia or schizoaffective disorder
  • 18 to 55 years of age
  • Stable treatment with a D2/5HT2A antagonists or a D2 partial agonist for a minimum of six months and receiving no more than two antipsychotics
  • Has an informant who is considered reliable to provide support and to help ensure compliance with study visits and protocol procedures
  • Body mass index (BMI) between 18 and 40 kg/m2 inclusive

Please note that this is not the full list of study eligibility criteria.

Study Title (brief): 
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 in Patients with Schizophrenia or Schizoaffective Disorder And Negative Symptoms
Study Description (brief): 

RO6889450 is a novel compound and a potent partial agonist of Trace Amine-Associated Receptor 1 (TAAR1) for the treatment of negative symptoms in schizophrenia. This site is conducting Part B (add-on therapy) wherein participants will be randomized 1:1:1 to 45 mg QD of RO6889450, 150 mg QD of RO6889450, or placebo for 12 weeks. Stratification will be based on BNSS avolition/apathy subscore (sum of items “behavior” and “internal experience”; ≤6 vs. >6), age (18-35 years vs. 36-55 years), sex, and antipsychotic treatment (1:1 stratification ratio between dopamine 2 receptor [D2]/serotonin 2A [5HT2A] receptor antagonists and D2 partial agonist).

Study Contact: 

For more information about this study, please contact Dr. Malathi Perugula, research coordinator, at 212-961-8992 or malathi.perugula@nki.rfmh.org.

Exclusion Criteria: 
  • Moderate to severe substance use disorder within six months (excluding nicotine or caffeine) as defined by DSM-5
  • Other current DSM-5 diagnosis (e.g., bipolar disorder, major depressive disorder)
  • Significant medical and/or major neurologic disorder impairing cognition
  • Positive urine drug screen for amphetamines, methamphetamines, opiates, buprenorphine, methadone, cannabinoids (including cannabidiol), cocaine and barbiturates
Study Location: 
Manhattan Psychiatric Center’s 125th Street Clinic -- 163 West 125th Street, 11th and 12th Floors, NY, NY 10027

Computerized facial and acoustic analysis during speech as a measurement of negative symptoms in schizophrenia

Dr. Anzalee Khan’s team is investigating an artificial intelligence (AI) enabled vocal and facial analysis, avatar driven software (called Neurological and Mental health Screening Instrument or NEMSI) to show good reliability and validity compared to existing clinician-administered psychiatric interview assessments, like: the Brief Negative Symptom Scale (BNSS), Positive and Negative Syndrome Scale (PANSS) Marder Negative Factor, and the Calgary Depression Scale (CDSS).

Study Length: 
One week
Disorder/Condition: 
Schizophrenia
Inclusion Criteria: 
  • Inpatients with DSM-5 diagnosis of schizophrenia
  • English-speaking
  • WRAT-4 reading ≥ 8th grade level
  • 18-60 years of age
  • Have negative symptoms: which includes diminished vocal expression, decreased or increased vocal production, and difference in intonations when speaking                                                                                                                                                                                                                                                                                                                                                                                          
Study Title (brief): 
Computerized facial and acoustic analysis during speech as a measurement of negative symptoms in schizophrenia
Study Description (brief): 

Dr. Anzalee Khan’s team is investigating an artificial intelligence (AI) enabled vocal and facial analysis, avatar driven software (called Neurological and Mental health Screening Instrument or NEMSI) to show good reliability and validity compared to existing clinician-administered psychiatric interview assessments, like: the Brief Negative Symptom Scale (BNSS), Positive and Negative Syndrome Scale (PANSS) Marder Negative Factor, and the Calgary Depression Scale (CDSS).

Study Contact: 

For more information about this study, please contact Shuaib Ahmad, research coordinator, at 646-766-5869 or Shuaib.Ahmad@omh.ny.gov.

Exclusion Criteria: 
  • Have another DSM-5 diagnosis such as schizoaffective disorder, bipolar disorder, major depressive disorder, or tardive dyskinesia that is moderate to severe or requires treatment
  • Significant medical and/or major neurologic disorder
  • Clinically relevant abnormal movement disorders
Study Location: 
Manhattan Psychiatric Center, Ward's Island Complex, NY

Virtual reality-based training for aggressive behaviors in individuals with severe mental illness: a feasibility and proof of concept study

This comparator study will explore the feasibility and efficacy of the novel TRIPP™ Virtual Reality (TRIPP VR) device, which presents to inpatients computer-generated images of soothing and colorful figures inducing a mindfulness state and its effect on impulsive aggressive behavior.  Participants will be randomized to the Virtual Reality and Mobile app groups and receive 3 sessions of mindfulness training each week for a total of 18 sessions (up to 180 minutes).

Study Length: 
Six weeks
Disorder/Condition: 
Schizophrenia
Inclusion Criteria: 
  • Male and female patients
  • 18-65 years of age
  • Diagnosis: Schizophrenia or Schizoaffective Disorder
  • Documented assault in the past year or a score of at least 5 on the Life History of Aggression (LHA)
Study Title (brief): 
Virtual reality-based training for aggressive behaviors in individuals with severe mental illness: a feasibility and proof of concept study
Study Description (brief): 

This comparator study will explore the feasibility and efficacy of the novel TRIPP™ Virtual Reality (TRIPP VR) device, which presents to inpatients computer-generated images of soothing and colorful figures inducing a mindfulness state and its effect on impulsive aggressive behavior.  Participants will be randomized to the Virtual Reality and Mobile app groups and receive 3 sessions of mindfulness training each week for a total of 18 sessions (up to 180 minutes).

Study Contact: 

Anzalee Khan, PhD, Co-Principal Investigator at 646-766-5876 or Anzalee.Khan@nki.rfmh.org

Exclusion Criteria: 
  • Non-English speaking
  • Substance abuse one month prior to baseline
  • Clinically unstable
  • History of traumatic brain disorder
Study Location: 
Manhattan Psychiatric Center, Ward's Island Complex, NY

ADNI 3 (Alzheimer’s Disease Neuroimaging Initiative)

This study is sponsored by the NIH and will employ cutting-edge techniques to evaluate normal and pathological brain aging which could help change the future of Alzheimer’s disease. Poor memory is often viewed as a simple sign of getting older, complicating our understanding and treatment of Alzheimer's disease. For more than a decade, ADNI researchers have worked tirelessly to better understand the disease and its progression in a way that will help the development of future treatment options, though no experimental medication will be involved in this study.

Study Length: 
The study is set to run up to 5 years depending on funding.
Disorder/Condition: 
Alzheimer's Disease
Inclusion Criteria: 

The study is open to both male and female subjects, aged 55-90 years.

Open to all ranges of cognitive function:

  • cognitively normal
  • Mild Cognitive Impairment (MCI)
  • Mild dementia due to Alzheimer’s
Study Title (brief): 
ADNI 3 (Alzheimer’s Disease Neuroimaging Initiative)
Study Description (brief): 

This study is sponsored by the NIH and will employ cutting-edge techniques to evaluate normal and pathological brain aging which could help change the future of Alzheimer’s disease. Poor memory is often viewed as a simple sign of getting older, complicating our understanding and treatment of Alzheimer's disease. For more than a decade, ADNI researchers have worked tirelessly to better understand the disease and its progression in a way that will help the development of future treatment options, though no experimental medication will be involved in this study.

Study Contact: 

Antero Sarreal, MD at 845-398-6532 or asarreal@nki.rfmh.org.

Neurobiology of sensory phenomena in obsessive-compulsive disorder

This project investigates brain function associated with sensory symptoms in patients with obsessive-compulsive disorder (OCD) and their siblings using magnetic resonance imaging (MRI). Participants will have a comprehensive symptom assessment during one visit, and an MRI scan at the second visit.

Study Length: 
2 study visits, with each visit taking approximately 3-4 hours, over the course of 1-3 weeks. The total number of hours will be approximately 6-8.
Disorder/Condition: 
Obsessive-Compulsive Disorder (OCD)
Inclusion Criteria: 

Men and women between the ages of 18 and 60 who have obsessive-compulsive disorder or have a biological sibling with obsessive compulsive disorder. Participants should be in good general health.

Study Title (brief): 
Neurobiology of sensory phenomena in obsessive-compulsive disorder
Study Description (brief): 

This project investigates brain function associated with sensory symptoms in patients with obsessive-compulsive disorder (OCD) and their siblings using magnetic resonance imaging (MRI). Participants will have a comprehensive symptom assessment during one visit, and an MRI scan at the second visit.

Study Contact: 

Nicolette Recchia at 845-398-5590 or pnclab@nki.rfmh.org.

Study Location: 
Nathan Kline Institute, Orangeburg, NY and New York University Medical Center, NY, NY

Schizophrenia Registry

The purpose of this project is to create a database, which will allow us to contact participants for active studies as well as other research opportunities within our program.

This database registry project is designed to give an opportunity to interested patients with schizophrenia or schizoaffective disorder to have access to the various research studies that the MPC Research Program has available.

Study Length: 
One time registration
Disorder/Condition: 
Schizophrenia or Schizoaffective Disorder
Inclusion Criteria: 
  • Male and female patients
  • 18-65 years of age
  • Diagnosis: Schizophrenia or Schizoaffective Disorder 
Study Title (brief): 
Schizophrenia Registry
Study Description (brief): 

The purpose of this project is to create a database, which will allow us to contact participants for active studies as well as other research opportunities within our program.

This database registry project is designed to give an opportunity to interested patients with schizophrenia or schizoaffective disorder to have access to the various research studies that the MPC Research Program has available.

Study Contact: 

Mohan Parak, M.D., Study Coordinator at 212-961-4016 or Mohan.parak@omh.ny.gov

Exclusion Criteria: 
  • Non-English speaking patients
  • Pregnancy
Study Location: 
Manhattan Psychiatric Center’s 125th Street Clinic, 163 West 125th Street, NY

The AZTherapies Study

This study is sponsored by AZTherapies, Inc. The clinical research study AZT-001 is being conducted to assess whether to test the effects of two drugs on memory - cromolyn sodium and ibuprofen - in people with clinical signs and symptoms of early Alzheimer’s disease (AD). Cromolyn sodium is taken using a mouth inhaler device (similar to those used in the treatment of asthma) once a day, and ibuprofen is taken orally (by mouth) as a tablet once a day. Both of these drugs are approved by the FDA for use in the treatment of asthma and inflammation, respectively.

These two drugs have never been tested as a combination treatment for AD and the use of these drugs, either alone or in combination, is not approved by the FDA for the treatment of AD. This research will investigate whether one drug or the combination of the two has any effect on memory problems associated with AD. Cromolyn has been found to block the production of toxic forms of the Abeta protein which have been implicated in the development and progression of AD. Ibuprofen dampens the neuroinflammation which is also found in the brains of AD patients. Thus, together these drugs may contribute both to the prevention of AD as well as slowing its progression. This study will also examine any side-effects that people may experience.

Study Length: 
The double-blind phase of the study will last 72 weeks or approximately 1 ½ years.
Disorder/Condition: 
Alzheimer's Disease
Inclusion Criteria: 

The study is open to both male and female subjects aged 55-79 years diagnosed with early stage AD.

Study Title (brief): 
The AZTherapies Study
Study Description (brief): 

This study is sponsored by AZTherapies, Inc. The clinical research study AZT-001 is being conducted to assess whether to test the effects of two drugs on memory - cromolyn sodium and ibuprofen - in people with clinical signs and symptoms of early Alzheimer’s disease (AD). Cromolyn sodium is taken using a mouth inhaler device (similar to those used in the treatment of asthma) once a day, and ibuprofen is taken orally (by mouth) as a tablet once a day. Both of these drugs are approved by the FDA for use in the treatment of asthma and inflammation, respectively.

Study Contact: 

Raymundo Hernando, MD at 845-398-5578 or hernando@nki.rfmh.org

The Triad Study (Avanir)

This clinical trial sponsored by AVANIR pharmaceuticals has a double-blind and an open label-phase. This study will investigate the effectiveness of an experimental drug for the treatment of agitation in individuals with Alzheimer’s disease. Agitation is quite common in this patient population (includes the following types of behaviors: screaming, cussing, destroying objects, grabbing, fighting, and pacing) and can be extremely distressing to the individual, the family, and caregivers, and generally does not respond to conventional medications.

The experimental drug that will be used in this study, dextromethorphan, is the active ingredient used in over-the-counter cough syrup medicines and of a medication which has been approved by the FDA for the treatment of uncontrollable crying/laughing associated with psuedobulbar palsy.

Study Length: 
The double-blind phase of the study will last 3 months and the open-label extension phase of the study will last up to 12 months.
Disorder/Condition: 
Alzheimer's Disease and Agitation
Inclusion Criteria: 

Potential subjects must be between 50-90 years old with clinically significant, moderate/severe agitation secondary to dementia of the Alzheimer’s type. The subjects must score between 6 – 26 on the Folstein (MMSE).

Study Title (brief): 
The Triad Study (Avanir)
Study Description (brief): 

This clinical trial sponsored by AVANIR pharmaceuticals has a double-blind and an open label-phase. This study will investigate the effectiveness of an experimental drug for the treatment of agitation in individuals with Alzheimer’s disease. Agitation is quite common in this patient population (includes the following types of behaviors: screaming, cussing, destroying objects, grabbing, fighting, and pacing) and can be extremely distressing to the individual, the family, and caregivers, and generally does not respond to conventional medications.

Study Contact: 

Antero Sarreal, MD at 845-398-6532 or asarreal@nki.rfmh.org

The EARLY Study (Janssen)

The EARLY Trial is being conducted to evaluate the safety and effectiveness of an investigational medication called JNJ-54861911, to determine whether it can prevent memory loss associated with Alzheimer’s disease. JNJ-54861911 has been designed to reduce the activity of a substance in the brain involved in producing beta-amyloid. Beta-amyloid is a protein that is normally produced and quickly cleared from the brain. Accumulation of beta-amyloid in the brain, resulting in amyloid plaques, is associated with the development of Alzheimer’s disease dementia. Evidence of amyloid plaque buildup in people with normal memory function has been linked to an increased risk for developing Alzheimer’s disease dementia in their future. Dementia due to Alzheimer’s disease is characterized by a progressive decline in memory and other thinking abilities (eg, difficulties with problem-solving or formulating speech), severe enough to limit a person’s independent daily function. The EARLY Trial will help us to better understand the relationship between amyloid, memory loss, and the development of Alzheimer’s disease dementia. Participants will be in the EARLY Trial for about 5 years.

Study Length: 
Participants will be in the EARLY Trial for about 5 years.
Disorder/Condition: 
Alzheimer's Disease
Study Title (brief): 
The EARLY Study (Janssen)
Study Description (brief): 

The EARLY Trial is being conducted to evaluate the safety and effectiveness of an investigational medication called JNJ-54861911, to determine whether it can prevent memory loss associated with Alzheimer’s disease.

Study Contact: 

For more information, please contact Raymundo Hernando at (845) 398-5578 or hernando@nki.rfmh.org.

The Generation Study (Novartis)

This study is sponsored by the NIH, and the pharmaceutical company Novartis in partnership with the Banner Alzheimer’s Institute. The clinical research study CAPI015A2201J is being conducted to assess whether CAD106 is safe and has beneficial effects in people who may be at elevated risk for the onset of clinical symptoms of Alzheimer’s disease due to their age and genetic status (carrying two copies of a version of the APOE gene called APOE-ε4 allele). Additionally, this study will examine the effects of each of the two therapies CAD 106 and CNP520 given separately and targeting brain amyloid on cognition, global clinical status, and underlying pathology in participants at risk for the onset of clinical symptoms of AD. 

Study Length: 
The double-blind phase of the study will last a possible minimum of 60 months.
Disorder/Condition: 
Alzheimer's Disease
Inclusion Criteria: 

Potential subjects must be cognitively intact individuals with 2 copies of the APOE-ε4 allele, age 60 to 75 years, inclusive, selected as they represent a population at particularly high risk of progression to MCI due to AD and/or dementia due to AD. The subject must score greater than a 24 on the Folstein (MMSE).

Study Title (brief): 
The Generation Study (Novartis)
Study Description (brief): 

The clinical research study CAPI015A2201J is being conducted to assess whether CAD106 is safe and has beneficial effects in people who may be at elevated risk for the onset of clinical symptoms of Alzheimer’s disease due to their age and genetic status (carrying two copies of a version of the APOE gene called APOE-ε4 allele).

Study Contact: 

For more information, please contact Katie Brundage at (845) 398-6533 or katherine.brundage@nki.rfmh.org.

Study Location: 
Nathan Kline Institute -- Orangeburg, NY

The Memory Education and Research Initiative (MERI Program)

Goals:

  • To communicate the results of these evaluations to participants and their personal physicians, if requested
  • To allow a baseline cognitive performance to be established for healthy individuals with no memory complaints but with a family history of AD or other dementias
  • To alert community health professionals about ongoing clinical studies for the treatment of memory disorders
  • To bring advances in basic research of Alzheimer’s disease and related disorders to clinical research studies
  • To educate participants about healthy brain aging

The MERI visit: The initial evaluation is usually completed in 1 visit, and lasts approximately 3 hours. Patients are encouraged to bring a family member or caregiver to the appointment.

Benefits of the MERI: Upon completion of the evaluation, all assessments will be scored and entered into a secure database. Results will be discussed among the doctors and psychologists of our team. A summary of this evaluation will be mailed out to you (and/or your physician if you so wish) in approximately 2-3 weeks. This report will contain findings about your general intellectual function, memory, and psychomotor function, as well as brief comments and recommendations.

Disorder/Condition: 
Alzheimer's disease; Memory evaluation
Study Title (brief): 
The Memory Education and Research Initiative (MERI Program)
Study Description (brief): 

The MERI program offers a comprehensive memory and cognitive evaluation at no cost, to individuals with memory complaints or a family history of Alzheimer’s disease (AD).

Study Contact: 

To learn more about the MERI Program, visit our website: http://geri.rfmh.org, or call 845-398-5584.

Volunteer Recruitment Pool

The Volunteer Recruitment Pool (VRP) is the primary entry point for individuals (ages 6 and up) who are interested in research participation at the Nathan Kline Institute (NKI).  After scheduling an appointment with a staff member in the Clinical Evaluation Center (CEC), interested individuals visit NKI for about 90 minutes.  During this time, they first learn more about the VRP and have their questions answered.  If they remain interested in participating, some basic information is collected (including contact information and basic medical history).  The individual then has an interview (usually about one hour in length) to review past and present mental health symptoms, if any.  For children (under 18 years old), the parent/guardian is also required and the interview is usually about 2 hours.  Feedback is provided to children and their guardian.  Adult VRP participants receive $20 for their time.  The information collected is then stored in a protected and confidential database within CEC.  The CEC then uses this information to match VRP participants with NKI research scientists who are investigating scientific questions.  If there is a match, NKI staff will contact the VRP participant to present the research opportunity.  All research programs, including the VRP, are voluntary at NKI.  If you are interested, please contact us at: 845-398-2184 or vrp@nki.rfmh.org.

Study Title (brief): 
Volunteer Recruitment Pool
Study Description (brief): 

The Volunteer Recruitment Pool (VRP) is the primary entry point for individuals (ages 6 and up) who are interested in research participation at the Nathan Kline Institute (NKI).  

Rockland Sample

The NKI Rockland Sample Initiative is a landmark research program aiming to map the brain, understand how it develops and changes over the course of life, and explore the connections between our brain and behavior.  Studies like this have the potential to change how we treat diseases from depression to Alzheimer’s.

This research program offers an opportunity for people of all ages—from 6 to 85—who live in Rockland County and neighboring areas to make a real difference. Over 1,400 residents have made the call and joined in the Rockland Sample, but we still need hundreds more. Here you can learn about our studies and the science behind them, and find out about the free programs we offer to schools and community organizations.

Find Out More (http://rocklandsample.org)

Study Title (brief): 
Rockland Sample
Study Description (brief): 

This research program offers an opportunity for people of all ages—from 6 to 85—who live in Rockland County and neighboring areas to make a real difference.

Yotam Sagi, Ph.D.

Yotam Sagi, Ph.D.

Assistant Research Scientist
Center for Dementia Research

Faculty Directory

Close

The goal of my research is to identify new molecular mechanisms in neuronal types in regulating resilience, depression and cognition, and to elucidate the mechanisms of action of slow-acting and fast-acting antidepressants. I use cell type specific molecular tools to identify molecules, cell types, neuronal functions, and signaling pathways in rodent models. I implement behavioral paradigms and use cell-type specific molecular tools, chemogenetics, and in vivo photometry in transgenic mice to identify the roles of new molecules in specific cell types in learning and in inducing resilience to stress. Thus far, my studies elucidated novel roles for inhibitory interneuron populations in the ventral dentate gyrus in mediating anhedonia, susceptibility and resilience to stress, and cognition.

Select Publications

Umschweif G, Medrihan L, Guillén-Samander A, Wang, W, Sagi Y, Greengard P (2021). Identification of Neurensin-2 as a novel modulator of emotional behavior, Mol. Psy. (Epub. DOI 10.1038/s41380-021-01058-5).

Umschweif G, Medrihan L, McCabe KA, Sagi Y, Greengard P (2021). Activation of the p11/SMARCA3/Neurensin-2 pathway in parvalbumin interneurons mediates the response to chronic antidepressants, Mol. Psy. (Epub. DOI 10.1038/s41380-021-01059-4).

Medrihan L, Umschweif G, Sinha A, Reed S, Gindinova K, Sinha SC, Greengard P, Sagi Y (2020). Reduced Kv3.1 activity in dentate gyrus parvalbumin cells induces vulnerability to depression. Biol. Psy. 88(5):405-414.

Hur JY, Frost GR, Wu X, Crump C, Pan SJ, Wong E, Barros M, Li T, Nie P, Zhai Y, Wang J, Chyong J, Guo L, McKenzie A, Ming C, Zhou X, Wang M, Sagi Y, Renton A, Esposito B, Kim Y, Sadleir KR, Trinh I, Rissman R, Vassar R, Zhang B, Johnson D, Masliah E, Greengard P, Goate A, Li Y (2020). Innate immunity protein IFITM3 modulates γ-secretase in Alzheimer disease. Nature 586(7831):735-740.

Umschweif G, Greengard P, Sagi Y (2021). The dentate gyrus in depression. Eur J. Neurosc. 53(1):39-64.

Sagi Y, Medrihan L, George K, Barney M, McCabe KA, Greengard P (2020). Emergence of 5-HT5A signaling in parvalbumin neurons mediates delayed antidepressant action. Mol. Psy. 25(6):1191-1201.

Medrihan L, Sagi Y, Inde Z, Krupa O, Daniels C, Peyrache A, Greengard P (2017). Initiation of behavioral response to antidepressants by cholecystokinin neurons of the dentate gyrus. Neuron 95(3): 564-576

Ayana Jordan, M.D., Ph.D.

Ayana Jordan, M.D., Ph.D.

Research Psychiatrist
Social Solutions & Services
845-398-6596

Faculty Directory

Close

Ayana Jordan, MD, PhD, joined NKI as a Research Psychiatrist in 2022. Dr. Jordan is an Addiction Psychiatrist and the Barbara Wilson Endowed Associate Professor of Psychiatry in the Department of Psychiatry, with a secondary appointment in Population Health at NYU Grossman School of Medicine and Pillar Co-Lead for Community Engagement at NYU Langone’s Institute for Excellence in Health Equity. She is dedicated to creating spaces and opportunities for more people of color, specifically Black women in academia who are vastly underrepresented. The fundamental message of equity and inclusion has informed her research, clinical work, and leadership duties at NYU and beyond. For instance, Dr. Jordan was the first Black Associate Program Director for the Yale Psychiatry Residency, her immediate past academic home, supervising a large group of 64 physicians providing mental health and addiction services throughout Yale medical systems in the state of Connecticut.

She recently became Director of the Equity, Diversity, and Inclusion initiative for the Justice Community Opioid Innovation Network within the National Institute of Drug (Ab)use, where she’ll be working to improve health outcomes for people with opioid use disorder in the carceral system. Dr. Jordan also serves as the medical director of Recognizing and Eliminating disparities in Addiction through Culturally informed Healthcare or (REACH), a Substance (Ab)use and Mental Health Services Administration grant, in conjunction with the American Academy of Addiction Psychiatry, geared toward increasing the number of addiction specialists from racial and ethnic minoritized populations who obtain training to provide culturally informed addiction treatment. Passionate about helping racial and ethnic minoritized people achieve wellness and recovery from substance use disorders, Dr. Jordan was fully drawn to community-based research. Dr. Jordan is an NIH-funded researcher where she studies long term outcomes for providing addiction treatment in faith settings.

She is elated and inspired to exist in an environment supportive of her vision to work with communities, integrating the cultural and religious aspects of people’s lives, while also addressing structural inequities that impede improved mental health and wellness. She is deeply grateful to be taking care of the most historically excluded patients during this time, who are facing extreme challenges in obtaining addiction treatment due to COVID-19. Dr. Jordan is the proud recipient of various clinical and research awards and was inducted into the Top 40 under 40 society by her undergraduate alma mater, Hampton University, a historically Black institution.

Eduardo Gonzalez-Moreira, Ph.D.

Eduardo Gonzalez-Moreira, Ph.D.

Research Scientist
Center for Biomedical Imaging & Neuromodulation
845-398-5507

Faculty Directory

Close

Dr. Gonzalez-Moreira is a research scientist in the Center for Biomedical Imaging and Neuromodulation at NKI. He studied Telecommunication and Electronic Engineering at Universidad Central “Marta Abreu” de Las Villas (UCLV), Cuba, from 1999 to 2004, with a special focus on digital signal processing. In 2005 he obtained a scholarship from the Chinese Government which allowed him to complete a PhD at Zhejiang University, China, under the supervision of Guan Li, Walter J. Freeman, and Hans Liljenström. From 2004 to 2016 he worked as a professor at Faculty of Electrical Engineering, UCLV. Dr Gonzalez-Moreira went on to complete a Postdoctoral Fellowship under the supervision of Pedro A. Valdes-Sosa at the Clinical Hospital of Chengdu Brain Science Institute, China, from 2016-2018. From 2019-2022, he worked under the supervision of Thalia Harmony on EEG data analysis for characterization of preterm infants with risk factors for brain damage, at the Neurodevelopmental Research Unit, Institute of Neurobiology of the National Autonomous University of Mexico, Mexico. Dr. Gonzalez-Moreira’s long-term research interests involve computational neuroscience for estimation of neural activity and connectivity based on non-invasive electrophysiological recordings, and biomarker assessment for characterization of neurodegenerative diseases.

Carla Nasca, Ph.D.

Carla Nasca, Ph.D.

Research Scientist
Center for Dementia Research

Faculty Directory

Close

Dr. Carla Nasca's Epigenetics and System Neuroscience laboratory is working on an innovative model of epigenetic mechanisms of neuroplasticity to stress with a new angle on the communication between mitochondria and cell nuclei. Key to this framework is the pivotal mitochondrial metabolite L-acetyl-carnitine or LAC, which our group discovered as a novel epigenetic modulator of glutamatergic function and a promising therapeutic target for clinical endophenotypes of depression – a prodrome to Alzheimer’s Disease. Her laboratory also uses computational approaches together with emerging technologies to isolate patient-derived exosomes for identifying in vivo neural mechanisms of main CNS diseases (mood and cognitive disorders) and potential biomarkers of the responses to antidepressant candidates (LAC), drugs (ketamine) and brain stimulation (TMS).

Dr. Nasca's research has been recognized with awards from the Blavatnik Foundation for Innovative Research, the Hope for Depression Research Foundation, the American Foundation for Suicide Prevention, the Brain and Behavior Research Foundation and the Falk Foundation for Transformative Research.

If interested in a Postdoctoral Research or Assistant Research Scientist position,

please email to

carla.nasca@nyulangone.org or

carla.nasca@nki.rfmh.org

Select Publications

Nasca C, Dobbin J, Bigio B, Watson K, de Angelis P, Kautz M, Cochran A, Mathé AA, Kocsis JH, Lee FS, Murrough JW, McEwen BS, Rasgon N. Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance. Mol Psychiatry. 2021 Sep;26(9):5140-5149. doi: 10.1038/s41380-020-0804-7. Epub 2020 Jun 15. PMID: 32536688; PMCID: PMC7787430.

Nasca C, Menard C, Hodes G, Bigio B, Pena C, Lorsch Z, Zelli D, Ferris A, Kana V, Purushothaman I, Dobbin J, Nassim M, DeAngelis P, Merad M, Rasgon N, Meaney M, Nestler EJ, McEwen BS, Russo SJ. Multidimensional Predictors of Susceptibility and Resilience to Social Defeat Stress. Biol Psychiatry. 2019 Sep 15;86(6):483-491. doi: 10.1016/j.biopsych.2019.06.030. Epub 2019 Jul 29. PMID: 31466563; PMCID: PMC6730655.

Nasca C, Bigio B, Lee FS, Young SP, Kautz MM, Albright A, Beasley J, Millington DS, Mathé AA, Kocsis JH, Murrough JW, McEwen BS, Rasgon N. Acetyl-l-carnitine deficiency in patients with major depressive disorder. Proc Natl Acad Sci U S A. 2018 Aug 21;115(34):8627-8632. doi: 10.1073/pnas.1801609115. Epub 2018 Jul 30. PMID: 30061399; PMCID: PMC6112703.

Nasca C, Bigio B, Zelli D, de Angelis P, Lau T, Okamoto M, Soya H, Ni J, Brichta L, Greengard P, Neve RL, Lee FS, McEwen BS. Role of the Astroglial Glutamate Exchanger xCT in Ventral Hippocampus in Resilience to Stress. Neuron. 2017 Oct 11;96(2):402-413.e5. doi: 10.1016/j.neuron.2017.09.020. PMID: 29024663.

Bigio B, Mathé AA, Sousa VC, Zelli D, Svenningsson P, McEwen BS, Nasca C. Epigenetics and energetics in ventral hippocampus mediate rapid antidepressant action: Implications for treatment resistance. Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7906-11. doi: 10.1073/pnas.1603111113. Epub 2016 Jun 27. PMID: 27354525; PMCID: PMC4948346.

Kuldeep Sachdeva, Ph.D.

Kuldeep Sachdeva, Ph.D.

Postdoctoral Fellow
Center for Dementia Research

Faculty Directory

Close

Kuldeep completed his undergraduate studies in Biotechnology at the Kurukshetra University in India followed by a master’s degree in Molecular Biology and Biotechnology at CCS Haryana Agriculture University (CCSHAU). Under the supervision of Professor Virendra K. Sikka at CCSHAU, Kuldeep pathotyped the leaf-curl virus strains in cotton leaf-curl disease samples. In 2014, Kuldeep joined the National Centre for Biological Sciences (NCBS | TIFR) at Bengaluru, India for his Ph.D. under the supervision of Dr. Varadharajan Sundaramurthy. There, he investigated modulations in the host Endo-Lysosomal network upon Mycobacterium tuberculosis (the tuberculosis disease-causing pathogen) infection in both in vitro and in vivo model systems. Kuldeep has now joined Professor Ralph Nixon's group at the Nathan Kline Institute and will be working on Alzheimer’s disease.

Alysse Woods

Alysse Woods

IRB Director
Institutional Review Board
845-398-5492

Faculty Directory

Close

After completing her bachelor’s degree in Psychology at Indiana University, Alysse Woods began her career as a Research Scientist in the Behavioral Science and Leadership Department of the United States Military Academy, West Point, where she worked with military personnel and mentored cadets for 11 years. For the first 7 years at the Academy, the focus of her research was cyber security and behavioral biometrics, working as a lead on many Defense Advanced Research Project Agency programs. She went on to become the Regulatory Compliance Officer for the Orthopaedic and Sports Medicine Research John A. Feagin Jr. Sports Medicine Fellowship at West Point’s Keller Army Community Hospital, where her main area of focus turned to regulations and protections of human subjects in concussion research that included all 4 service academies and 29 civilian universities, led by the NCAA-DoD Grand Alliance CARE Consortium. Ms. Woods also served on the Academy’s Institutional Review Board, the CAIRB.